Nektar Therapeutics Income Statement - Quarterly (NASDAQ:NKTR)

Add to My Stocks
$22.53 $0.36 (1.57%) NKTR stock closing price Mar 23, 2017 (Closing)

Financial analysis of Nektar Therapeutics involves more than just checking the Nektar Therapeutics stock price, by looking at the financial statements of the company in detail. An income statement is one of the three key financial statements furnished by a company, the other two being the balance sheet and the cashflow statement. The income statement for NKTR which implies a QoQ revenue growth of $1.11M is specific to a period of time. Investors typically check YoY or QoQ revenue growth. Along with Nektar Therapeutics assets and Nektar Therapeutics free cash flow, profits as shown in profit and loss statement give key insights about the business. The profits have increased from $-43.22M QoQ and 2016-Q4 revenue is $37.45M. View details of revenue and profits for Nektar Therapeutics for latest & last 40 quarters.

show more
Annual
Quarterly
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3
Nektar Therapeutics Net Sales or Revenues
37.45M36.34M32.77M58.88M39.37M59.95M22.66M108.8M19.55M132.87M
Cost Of Goods Sold (COGS)6.6M7.03M7.7M8.87M8.37M6.76M10.53M8.44M6.31M9.22M
Nektar Therapeutics Gross Profit
30.85M29.3M25.06M50.01M31.02M53.19M12.12M100.35M13.26M123.65M
Research & Development Expense50.23M51.95M52.35M49.26M47.14M43.22M45.41M47.01M38.5M34.2M
Selling General & Admin Expense12.76M10.25M11.03M10.22M13.24M9.54M10.18M10.3M12.26M9.13M
Income Before Depreciation Depletion Amortization-32.14M-32.9M-38.32M-9.48M-29.36M0.41M-43.46M43.04M-37.49M80.32M
Depreciation Depletion Amortization----------
Non Operating Income0.72M0.33M0.45M0.87M-13.73M0.89M0.24M0.21M0.29M0.12M
Interest Expense10.33M10.51M10.6M10.72M10.99M9.42M9.27M9.22M9.62M9.59M
Nektar Therapeutics Pretax Income
-41.76M-43.08M-48.47M-19.33M-54.1M-8.11M-52.49M34.03M-46.82M70.85M
Provision for Income Taxes0.44M0.13M0.12M0.16M0.04M0.09M0.16M0.21M-1.13M0.24M
Minority Interest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-42.2M-43.22M-48.6M-19.5M-54.14M-8.2M-52.66M33.82M-45.68M70.61M
Extraordinary Items & Discontinued Operations----------
Nektar Therapeutics Net Income (Profit/Loss)
-42.2M-43.22M-48.6M-19.5M-54.14M-8.2M-52.66M33.82M-45.68M70.61M
Average Shares used to compute Diluted EPS149.07M137.09M136.35M135.79M134.17M132.63M131.64M135.67M129.33M132.18M
Average Shares used to compute Basic EPS149.07M137.09M136.35M135.79M134.17M132.63M131.64M131.36M129.33M127.5M
Income Before Nonrecurring Items-42.2M-43.22M-48.6M-19.5M-54.14M-8.2M-52.66M33.82M-45.68M70.61M
Income from Nonrecurring Items----------
Nektar Therapeutics Earnings Per Share Basic Net
-0.28-0.32-0.36-0.14-0.40-0.06-0.400.26-0.350.55
Nektar Therapeutics Earnings Per Share Diluted Net
-0.28-0.32-0.36-0.14-0.40-0.06-0.400.25-0.350.53
EPS Diluted Before Nonrecurring Items-0.28-0.32-0.36-0.14-0.40-0.06-0.400.25-0.350.53
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common----------
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Income statement for another ticker

1:22
NKTR
Nektar Therapeutics stock analysis involves checking at least a few of the important things like:
  • Revenue: This is the inflow that is generated from the sale of goods or services and is $37.45M for this quarter of 2016-Q4. Our Nektar Therapeutics revenue chart gives a clear visual representation of how the topline growth has been. Investors often invest in only those companies where the revenue is growing at a steady rate.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. NKTR stock had a healthy bottom line growth.
The income statement is also called statement of revenue and expense. The financials along with Nektar Therapeutics historical stock prices provides a lot of details about the firm. .

Nektar Therapeutics Income Statement - Key Financial Ratios

PS ratio (
price sales ratio
)
20.3007
Operating margin
-90.5
Net profit margin
-118.9
Dividend yield
0%